Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem

被引：9

作者：

Yoon, Stephanie C. ^{[1
,2
]}

Bruner, Heather C. ^{[3
]}

机构：

[1] Scripps Hlth, San Diego, CA USA

[2] Univ Calif San Diego, Joint Hosp & Palliat Med Fellowship, San Diego, CA 92103 USA

[3] Univ Calif San Diego, Dept Med, Doris A Howell Palliat Care Serv, La Jolla, CA 92093 USA

来源：

PATIENT PREFERENCE AND ADHERENCE | 2017年 / 11卷

关键词：

opioid-induced constipation; chronic pain; bowel care; peripherally acting mu-opioid-receptor antagonist; OIBD; INDUCED BOWEL DYSFUNCTION; LONG-TERM SAFETY; NONCANCER PAIN; DOUBLE-BLIND; CANCER PAIN; TOLERABILITY; MANAGEMENT; PHARMACOKINETICS; IMPAIRMENT; PREVALENCE;

D O I：

10.2147/PPA.S99412

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Opioid-induced constipation (OIC) imposes a significant burden for patients taking pain medications, often resulting in decreased quality of life. Treatment of OIC with traditional medications for functional constipation can be incompletely effective, leading to nonadherence with opioid treatment and undertreated pain. An emerging class of medications that counteract the adverse effects of opioids in the gastrointestinal tract while preserving central nervous system-based pain relief may represent a paradigm shift in the prevention and treatment of OIC. One of these medications, naloxegol, is a once-daily, oral opioid antagonist that is effective, well-tolerated, and approved for treatment of OIC in patients with noncancer pain. More studies are needed to demonstrate this same utility in patients with cancer-related pain.

引用

页码：1265 / 1271

页数：7

共 28 条

[1]

Abramowitz L, 2013, J Med Econ, V16, P1423, DOI 10.3111/13696998.2013.851082

[2] Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain [J].

Ahmedzai, Sam H. ;

Leppert, Wojciech ;

Janecki, Marcin ;

Pakosz, Artur ;

Lomax, Mark ;

Duerr, Heike ;

Hopp, Michael .

SUPPORTIVE CARE IN CANCER, 2015, 23 (03) :823-830

[3]

[Anonymous], 2013, ENT ALV PACK INS

[4]

[Anonymous], 2014, MOV NAL TABL PACK IN

[5] Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation [J].

Argoff, Charles E. ;

Brennan, Michael J. ;

Camilleri, Michael ;

Davies, Andrew ;

Fudin, Jeffrey ;

Galluzzi, Katherine E. ;

Gudin, Jeffrey ;

Lembo, Anthony ;

Stanos, Steven P. ;

Webster, Lynn R. .

PAIN MEDICINE, 2015, 16 (12) :2324-2337

[6] The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1) [J].

Bell, Timothy J. ;

Panchal, Sunil J. ;

Miaskowski, Christine ;

Bolge, Susan C. ;

Milanova, Tsveta ;

Williamson, Russell .

PAIN MEDICINE, 2009, 10 (01) :35-42

[7] Clinical utility of naloxegol in the treatment of opioid-induced constipation [J].

Bruner, Heather C. ;

Atayee, Rabia S. ;

Edmonds, Kyle P. ;

Buckholz, Gary T. .

JOURNAL OF PAIN RESEARCH, 2015, 8 :289-294

[8] The Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol [J].

Bui, Khanh ;

She, Fahua ;

Sostek, Mark .

JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12) :1375-1382

[9] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol [J].

Bui, Khanh ;

She, Fahua ;

Sostek, Mark .

JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12) :1368-1374

[10] Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation [J].

Camilleri, M. ;

Drossman, D. A. ;

Becker, G. ;

Webster, L. R. ;

Davies, A. N. ;

Mawe, G. M. .

NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (10) :1386-1395

← 1 2 3 →